mesЭкстремальная биомедицинаExtreme Medicine3033-89643033-8972Centre for Strategic Planning of the Federal Medical and Biological Agency10.47183/mes.2023.036mes-21Research ArticleОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕORIGINAL RESEARCHРазработка и оценка эффективности ранозаживляющих соединений на основе катионных пептидов и фуллеренаDeveloping and evaluating the effectiveness of wound-healing compounds based on cationic peptides and fullereneГалкинаА. А.GalkinaA. A.

Анастасия Андреевна Галкина

Каширское ш., д. 24, г. Москва, 115522

Anastasiia А. Galkina

Kashirskoe sh., 24, Moscow, 115522

anastasia.a.galkina@gmail.comБолякинаД. К.BolyakinaD. K.

Москва

Moscow

ШатиловаА. В.ShatilovaA. V.

Москва

Moscow

ШатиловА. А.ShatilovA. A.

Москва

Moscow

БабихинаМ. О.BabikhinaM. O.

Москва

Moscow

ГоломидоваА. К.GolomidovaA. K.

Москва

Moscow

АндреевС. М.AndreevS. M.

Москва

Moscow

ШершаковаН. Н.ShershakovaN. N.

Москва

Moscow

ХаитовМ. Р.KhaitovM. R.

Москва

Moscow

Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентствРоссияNational Research Center — Institute of Immunology of Federal Medical Biological AgencyRussian FederationФедеральный исследовательский центр «Фундаментальные основы биотехнологии» Российской академии наукРоссияFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of SciencesRussian FederationГосударственный научный центр «Институт иммунологии» Федерального медико-биологического агентств; Российский национальный исследовательский медицинский университет имени Н. И. ПироговаРоссияNational Research Center — Institute of Immunology of Federal Medical Biological Agency; Pirogov Russian National Research Medical UniversityRussian Federation2023221020242535664Copyright © Галкина А.А., Болякина Д.К., Шатилова А.В., Шатилов А.А., Бабихина М.О., Голомидова А.К., Андреев С.М., Шершакова Н.Н., Хаитов М.Р., 20242024Галкина А.А., Болякина Д.К., Шатилова А.В., Шатилов А.А., Бабихина М.О., Голомидова А.К., Андреев С.М., Шершакова Н.Н., Хаитов М.Р.Galkina A.A., Bolyakina D.K., Shatilova A.V., Shatilov A.A., Babikhina M.O., Golomidova A.K., Andreev S.M., Shershakova N.N., Khaitov M.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.extrememedicine.ru/jour/article/view/21

Инфекции кожи и мягких тканей при хирургических манипуляциях обычно вызваны широким спектром бактериальных микроорганизмов, и служат основной причиной септических осложнений и госпитальной смертности. Лечение таких ран является очень сложной проблемой, часто обусловленной переходом воспалительного процесса в хроническую стадию в связи с наличием устойчивой патогенной микрофлоры в раневой ткани. Целью работы было проанализировать ранозаживляющую активность мазевой композиции на основе водной дисперсии фуллерена С60 (ВДФ) на модели кожной травмы in vivo, оценить влияние ВДФ на экспрессию цитокинов как маркеров регенеративных процессов, определить антибактериальную активность разработанных нами катионных пептидов. ВДФ получали методом тангенциальной ультрафильтрации, а затем на ее основе готовили мазевую композицию. Моделирование кожной травмы проводили с использованием мышей линии BALB/c. Синтез катионных пептидов (КП) осуществляли твердофазным методом, используя Fmoc-технологию. Антибактериальную активность КП и ВДФ оценивали методом подсчета колоний. Установлено, что мазь на основе ВДФ обладала ранозаживляющей и противовоспалительной активностью. У наиболее активных КП, AB-1, AB-2, AB-3 и ST-10 минимальная бактерицидная концентрация (МБК) в отношении бактериального штамма E. coli Dh5 α составляла 1,15, 0,11, 0,74 и 0,74 мM, соответственно, при МБК ампициллина 0,7 мM. Мы предполагаем, что создание гибридных соединений/конъюгатов фуллерена С60 с активными КП будет перспективным направлением в разработке лекарственных средств для терапии раневых поражений, осложненных бактериальной инфекцией.

Skin and soft tissue infections following surgical procedures are usually caused by a broad range of bacteria and are the major cause of septic complications and hospital mortality. Treatment of such wounds is a challenge often resulting from the transition from acute to chronic inflammation due to persistence of pathogenic microflora in the wound tissue. The study was aimed to assess the wound-healing activity of the ointment composition based on the dispersion of fullerene C60 (AFD) in the in vivo model of skin wound, to estimate the effects of AFD on the expression of cytokines as markers of regenerative processes, to determine antibacterial activity of the developed cationic peptides. AFD was obtained by tangential ultrafiltration and used to make an ointment composition. The BALB/c mice were used to model the skin injury. The cationic peptides (CPs) were synthesized by the solid-phase method using the Fmoc technology. Antibacterial effects of CPs and AFD were estimated by colony counting. It was found that the AFD-based ointment exerted wound-healing and anti-inflammatory activity. The minimum bactericidal concentrations (MBC) of the CPs most active against the E. coli Dh5 α strain, AB-1, AB-2, AB-3, and ST-10, were 1.15, 0.11, 0.74, and 0.74 mM, respectively, while MBC of ampicillin was 0.7 mM. We assume that constructing the hybrid compounds/fullerene C60 conjugates with active CPs will be a promising area of the development of drugs for treatment of wounds complicated by bacterial infection.

водный раствор фуллерена С60ранозаживляющая активностькатионные пептидыантибактериальная активностьfullerene C60 aqua dispersionregenerative activitycationic peptidesantibacterial activityИсследование выполнено в рамках государственного задания ФМБА «Фуллерен-21» (код 612.017.1:616.9).The study was conducted as part of the State Assignment of FMBA “Fullerene-21” (code 612.017.1:616.9).ReferencesThe report "Scar Treatment Market Size, Share & Trends Analysis Report By Scar Type, By Product, By End Use And Segment Forecasts, 2019–2026". GLOBE NEWSWIRE. New York, 2019.The report "Scar Treatment Market Size, Share & Trends Analysis Report By Scar Type, By Product, By End Use And Segment Forecasts, 2019–2026". GLOBE NEWSWIRE. New York, 2019.Beyene RT, Derryberry SL Jr, Barbul A. The Effect of Comorbidities on Wound Healing. Surg Clin North Am. 2020; 100 (4): 695–705. DOI: 10.1016/j.suc.2020.05.002. Epub 2020 Jun 17. PMID: 32681870.Beyene RT, Derryberry SL Jr, Barbul A. The Effect of Comorbidities on Wound Healing. Surg Clin North Am. 2020; 100 (4): 695–705. DOI: 10.1016/j.suc.2020.05.002. Epub 2020 Jun 17. PMID: 32681870.Sachdeva C, Satyamoorthy K, Murali TS. Microbial Interplay in Skin and Chronic Wounds. Curr Clin Micro Rpt. 2022; 9: 21–31. DOI: 10.1007/s40588-022-00180-4.Sachdeva C, Satyamoorthy K, Murali TS. Microbial Interplay in Skin and Chronic Wounds. Curr Clin Micro Rpt. 2022; 9: 21–31. DOI: 10.1007/s40588-022-00180-4.Huszczynski SM, Lam JS, Khursigara CM. The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology. Pathogens. 2019; 9: 6. DOI: 10.3390/pathogens9010006.Huszczynski SM, Lam JS, Khursigara CM. The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology. Pathogens. 2019; 9: 6. DOI: 10.3390/pathogens9010006.Puca V, Marulli RZ, Grande R, Vitale I, Niro A, Molinaro G, et al. Microbial Species Isolated from Infected Wounds and Antimicrobial Resistance Analysis: Data Emerging from a Three– Years Retrospective Study. Antibiotics (Basel). 2021; 10 (10): 1162. PubMed PMID: 34680743; PubMed PMCID: PMC8532735.Puca V, Marulli RZ, Grande R, Vitale I, Niro A, Molinaro G, et al. Microbial Species Isolated from Infected Wounds and Antimicrobial Resistance Analysis: Data Emerging from a Three– Years Retrospective Study. Antibiotics (Basel). 2021; 10 (10): 1162. PubMed PMID: 34680743; PubMed PMCID: PMC8532735.Прохоров Д. В., Щербенёва А. А., Нгема М. В., Испирьян М. Б., Кузнецова М. Ю. Современные методы комплексного лечения и профилактики рубцов кожи. Крымский терапевтический журнал. 2021; 1: 26–31.Prohorov DV, Shherbenyova AA, Ngema MV, Ispiryan MB, Kuznecova MYu. Sovremennye metody kompleksnogo lecheniya i profilaktiki rubcov kozhi. Krymskij terapevticheskij zhurnal. 2021; 1: 26–31. Russian.Puca V, Traini T, Guarnieri S, Carradori S, Sisto F, Macchione N, et al. The Antibiofilm Effect of a Medical Device Containing TIAB on Microorganisms Associated with Surgical Site Infection. Molecules. 2019; 24 (12): 2280. PubMed PMID: 31248162; PubMed PMCID: PMC6630542.Puca V, Traini T, Guarnieri S, Carradori S, Sisto F, Macchione N, et al. The Antibiofilm Effect of a Medical Device Containing TIAB on Microorganisms Associated with Surgical Site Infection. Molecules. 2019; 24 (12): 2280. PubMed PMID: 31248162; PubMed PMCID: PMC6630542.Geitani R, Ayoub Moubareck C, Touqui L, Karam Sarkis D. Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol. 2019; 19 (1): 54.Geitani R, Ayoub Moubareck C, Touqui L, Karam Sarkis D. Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol. 2019; 19 (1): 54.Samanta I, Bandyopadhyay S. Streptococcus. In: Antimicrobial Resistance in Agriculture. United States Cambridge: Academic Press in an imprint of Elsevier, 2020; p. 217–232.Samanta I, Bandyopadhyay S. Streptococcus. In: Antimicrobial Resistance in Agriculture. United States Cambridge: Academic Press in an imprint of Elsevier, 2020; p. 217–232.Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020; 19: 311–32. DOI: 10.1038/s41573-019-0058-8.Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020; 19: 311–32. DOI: 10.1038/s41573-019-0058-8.Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003; 38 (11–12): 913–23. PubMed PMID: 14642323.Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003; 38 (11–12): 913–23. PubMed PMID: 14642323.Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005; 5 (12): 2578–85. PubMed PMID: 16351219.Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005; 5 (12): 2578–85. PubMed PMID: 16351219.Zhou Z, Joslin S, Dellinger A, Ehrich M, Brooks B, Ren Q, et al. A novel class of compounds with cutaneous wound healing properties. J Biomed Nanotechnol. 2010; 6 (5): 605–11. PubMed PMID: 21329053.Zhou Z, Joslin S, Dellinger A, Ehrich M, Brooks B, Ren Q, et al. A novel class of compounds with cutaneous wound healing properties. J Biomed Nanotechnol. 2010; 6 (5): 605–11. PubMed PMID: 21329053.Andreev S, Purgina D, Bashkatova E, Garshev A, Maerle A, Andreev I, et al. Study of fullerene aqueous dispersion prepared by novel dialysis method: simple way to fullerene aqueous solution. Fullerenes Nanotubes and Carbon Nanostructures. 2015; 23: 792–800.Andreev S, Purgina D, Bashkatova E, Garshev A, Maerle A, Andreev I, et al. Study of fullerene aqueous dispersion prepared by novel dialysis method: simple way to fullerene aqueous solution. Fullerenes Nanotubes and Carbon Nanostructures. 2015; 23: 792–800.Shershakova NN, Andreev SM, Tomchuk AA, Makarova EA, Nikonova AA, Turetskiy EA, et al. Wound healing activity of aqueous dispersion of fullerene C60 produced by "green technology". Nanomedicine. 2023; 47: 102619. Epub 2022 Oct 19.Shershakova NN, Andreev SM, Tomchuk AA, Makarova EA, Nikonova AA, Turetskiy EA, et al. Wound healing activity of aqueous dispersion of fullerene C60 produced by "green technology". Nanomedicine. 2023; 47: 102619. Epub 2022 Oct 19.Молчанова В. И., Чикаловец И. В., Черников О. В., Попов А. М., Кривошапко О. Н., Лукьянов П. А. Сравнительное изучение биологической активности биогликанов из дальневосточной мидии crenomytilus grayanus. Тихоокеанский медицинский журнал. 2012; 1 (47): 47–50.Molchanova VI, Chikalovec IV, Chernikov OV, Popov AM, Krivoshapko ON, Lukyanov PA. Sravnitel'noe izuchenie biologicheskoj aktivnosti bioglikanov iz dal'nevostochnoj midii crenomytilus grayanus. Tixookeanskij medicinskij zhurnal. 2012; 1 (47): 47–50. Russian.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real–time quantitative PCR and the 2(–Delta Delta C(T)) method. Methods. 2001; 25 (4): 402–8. PubMed PMID: 11846609.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real–time quantitative PCR and the 2(–Delta Delta C(T)) method. Methods. 2001; 25 (4): 402–8. PubMed PMID: 11846609.Шамова О. В., Жаркова М. С., Чернов А. Н., Владимирова Е. В., Сухарева М. С., Комлев А. С. и др. Антимикробные пептиды врожденного иммунитета как прототипы новых средств борьбы с антибиотикорезистентными бактериями. Российский журнал персонализированной медицины. 2021; 1 (1): 146–72.Shamova OV, Zharkova MS, Chernov AN, Vladimirova EV, Suxareva MS, Komlev AS. i dr. Antimikrobnye peptidy vrozhdennogo immuniteta kak prototipy novyx sredstv bor'by s antibiotikorezistentnymi bakteriyami. Rossijskij zhurnal personalizirovannoj mediciny. 2021; 1 (1): 146–72. Russian.Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, et al. Linear and dendrimeric antiviral peptides: Design, chemical synthesis and activity against human respiratory syncytial virus. J. Mater. Chemistry B. 2020; 8 (13): 2607–17. DOI: 10.1039/c9tb02485a.Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, et al. Linear and dendrimeric antiviral peptides: Design, chemical synthesis and activity against human respiratory syncytial virus. J. Mater. Chemistry B. 2020; 8 (13): 2607–17. DOI: 10.1039/c9tb02485a.Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003; 83 (3): 835–70. PubMed PMID: 12843410.Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003; 83 (3): 835–70. PubMed PMID: 12843410.Ashcroft GS, Jeong MJ, Ashworth JJ, Hardman M, Jin W, Moutsopoulos N, et al. Tumor necrosis factor-alpha (TNF-α is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen. 2012; 20 (1): 38–49. Epub 2011 Dec 8. PubMed PMID: 22151742; PubMed PMCID: PMC3287056.Ashcroft GS, Jeong MJ, Ashworth JJ, Hardman M, Jin W, Moutsopoulos N, et al. Tumor necrosis factor-alpha (TNF-α is a therapeutic target for impaired cutaneous wound healing. Wound Repair Regen. 2012; 20 (1): 38–49. Epub 2011 Dec 8. PubMed PMID: 22151742; PubMed PMCID: PMC3287056.Stockmann C, Kirmse S, Helfrich I, Weidemann A, Takeda N, Doedens A, et al. A wound size–dependent effect of myeloid cell– derived vascular endothelial growth factor on wound healing. J Invest Dermatol. 2011; 131 (3): 797–801. Epub 2010 Nov 25. PubMed PMID: 21107350.Stockmann C, Kirmse S, Helfrich I, Weidemann A, Takeda N, Doedens A, et al. A wound size–dependent effect of myeloid cell– derived vascular endothelial growth factor on wound healing. J Invest Dermatol. 2011; 131 (3): 797–801. Epub 2010 Nov 25. PubMed PMID: 21107350.Robertson FM, Pellegrini AE, Ross MR, Oberyszyn AS, Boros LG, Bijur GN, et al. Interleukin-1alpha gene expression during wound healing. Wound Rep Reg. 1995; 3 (4): 473–84. PubMed PMID: 17147659.Robertson FM, Pellegrini AE, Ross MR, Oberyszyn AS, Boros LG, Bijur GN, et al. Interleukin-1alpha gene expression during wound healing. Wound Rep Reg. 1995; 3 (4): 473–84. PubMed PMID: 17147659.Shershakova N, Baraboshkina E, Andreev S, Purgina D, Struchkova I, Kamyshnikov O, et al. Anti–inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnology. 2016; 14: 8. PubMed PMID: 26810232; PubMed PMCID: PMC4727272.Shershakova N, Baraboshkina E, Andreev S, Purgina D, Struchkova I, Kamyshnikov O, et al. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. J Nanobiotechnology. 2016; 14: 8. PubMed PMID: 26810232; PubMed PMCID: PMC4727272.Spohn R, Daruka L, Lázár V, et al. Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance. Nat Commun. 2019; 10 (1): 4538. PubMed PMID: 31586049; PubMed PMCID: PMC6778101.Spohn R, Daruka L, Lázár V, et al. Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance. Nat Commun. 2019; 10 (1): 4538. PubMed PMID: 31586049; PubMed PMCID: PMC6778101.Jangir PK, Ogunlana L, MacLean RC. Evolutionary constraints on the acquisition of antimicrobial peptide resistance in bacterial pathogens. Trends Microbiol. 2021; 29 (12): 1058–1061. Epub 2021 Apr 6. PubMed PMID: 33836929. PubMed PMID: 32355003; PubMed PMCID: PMC8097767.Jangir PK, Ogunlana L, MacLean RC. Evolutionary constraints on the acquisition of antimicrobial peptide resistance in bacterial pathogens. Trends Microbiol. 2021; 29 (12): 1058–1061. Epub 2021 Apr 6. PubMed PMID: 33836929. PubMed PMID: 32355003; PubMed PMCID: PMC8097767.Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020; 368 (6490): eaau5480. PubMed PMID: 32355003; PubMed PMCID: PMC8097767.Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020; 368 (6490): eaau5480. PubMed PMID: 32355003; PubMed PMCID: PMC8097767.Falanga A, Del Genio V, Galdiero S. Peptides and Dendrimers: How to Combat Viral and Bacterial Infections. Pharmaceutics. 2021; 13 (1): 101.Falanga A, Del Genio V, Galdiero S. Peptides and Dendrimers: How to Combat Viral and Bacterial Infections. Pharmaceutics. 2021; 13 (1): 101.

The authors declare that there are no conflicts of interest present.